The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
This site was built with web standards. You are currently viewing the unformatted version of the website. Please update your browser in order to view the site.
Internet Explorer 5 or greater
Netscape 7
Mozilla
Opera 6 or greater
VYTORIN is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, Apo B, TG, and non–HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia when diet alone is not enough.
Hypersensitivity to any component of this medication; active liver disease; unexplained persistent elevations of serum transaminases; and women who are pregnant, nursing, or may become pregnant.
VYTORIN contains 2 active ingredients: ezetimibe and simvastatin. No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.
The clinical impact of comparative differences in lipid changes between products is not known.
Click here for Selected Cautionary Information.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC.
Other brands listed are the trademarks of their respective owners and are not trademarks of MSP Singapore Company, LLC.
